^
    Back
    Association details:
    Biomarker:MET amplification
    Cancer:Gastric Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Matched therapies for advanced gastric cancer based on genotype: A real-world study in China.

    Published date:
    05/19/2021
    Excerpt:
    ...11 (37%) harbored c-MET amplification/overexpression (received savolitinib or crizotinib, cohort A)....three of 11 patients had an objective response (1 complete response and 2 partial responses, objective response rate (ORR) 27%), disease control rate (DCR) was 45%, median progression-free survival (mPFS) was 2.1 months, and median overall survival (mOS) was 3.7 months.
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer Ther
    Title:

    Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification

    Excerpt:
    Crizotinib also exhibited a marked antitumor effect in gastric cancer xenografts positive for MET amplification, whereas it had little effect on those negative for this genetic change. 
    DOI:
    10.1158/1535-7163.MCT-11-0934